-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Gc86gcvT3xQvnSNesuatGrsvacdelFJ0naxKO9cvhUFx30kVs463UK6tjzxCUJ4N MAl2bUIhgkUeDGtwBR+cYg== 0001144204-06-051147.txt : 20061204 0001144204-06-051147.hdr.sgml : 20061204 20061204162801 ACCESSION NUMBER: 0001144204-06-051147 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061127 ITEM INFORMATION: Other Events FILED AS OF DATE: 20061204 DATE AS OF CHANGE: 20061204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNESIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001061027 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943295878 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51531 FILM NUMBER: 061254535 BUSINESS ADDRESS: STREET 1: 341 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-3500 MAIL ADDRESS: STREET 1: 341 OYSTER POINT BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: MOSAIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19980709 8-K 1 v059602_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 27, 2006

SUNESIS PHARMACEUTICALS, INC.
 
(Exact Name of Registrant as Specified in its Charter)

     
Delaware
000-51531
94-3295878
(State or Other Jurisdiction
(Commission
(IRS Employer
of Incorporation)
File Number)
Identification No.)
     
341 Oyster Point Boulevard
  
South San Francisco, California 
94080 
(Address of Principal Executive Offices)
(Zip Code) 

Registrant’s telephone number, including area code: (650) 266-3500

Not Applicable
(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 8.01. Other Events. 
 
On November 27, 2006, and on November 28, 2006, Daryl B. Winter, Ph.D., Senior Vice President of Intellectual Property and Daniel C. Adelman, M.D., Senior Vice President, Research and Development of Sunesis Pharmaceuticals, Inc. (the “Company”), respectively, each adopted a Rule 10b5-1 trading plan (the “Plan”) with a broker. Each Plan specifies the number of shares of the Company’s common stock that may be sold and the market prices at which the sales should occur, subject to the terms and conditions of each such Plan. Each of Dr. Winter and Dr. Adelman entered into his Plan as part of his personal long-tem investment strategy for asset diversification and liquidity.

Pursuant to Dr. Winter’s Plan, the brokerage firm may exercise his employee stock options specified in the Plan representing up to 70,588 shares commencing in December 2006. The Plan is scheduled to terminate on August 31, 2007. The maximum number of shares that may be sold under this Plan, in addition to the Plan entered into by Dr. Winter on June 22, 2006, wherein 54,000 shares may be sold under that Plan, constitute approximately 52% of Dr. Winter’s holding of Company common stock, including vested and unvested stock options.

Pursuant to Dr. Adelman’s Plan, the brokerage firm may exercise his employee stock options specified in the Plan representing up to 30,000 shares commencing in December 2006. The Plan is scheduled to terminate on November 30, 2007. The maximum number of shares that may be sold under the Plan constitute approximately 12% of Dr. Adelman’s holding of Company common stock, including vested and unvested stock options.

Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, allows corporate insiders to establish pre-arranged written stock trading plans. A Plan must be entered into in good faith at a time when the insider is not aware of material, nonpublic information. As sales of common stock are executed in the future under the Plan, such sales will be reported in accordance with federal securities laws.


* * * * * * * * *

2

SIGNATURE(S)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
 
SUNESIS PHARMACEUTICALS, INC.
 
 		  
 		  
 
Date: December 4, 2006 
 By:   /s/ ERIC H. BJERKHOLT
  Eric H. Bjerkholt
 
Senior Vice President, Chief Financial Officer
 
3
 
 -----END PRIVACY-ENHANCED MESSAGE-----